SCHEMBL2923481

SCHEMBL2923481

O=C(O)Cc1cc(F)ccc1C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.50
KEAP1 Q14145 1/20 0.48
DCLRE1B Q9H816 2/20 0.47
AGBL2 Q5U5Z8 1/20 0.46
APEX1 P27695 1/20 0.44
CES2 O00748 2/20 0.44
CES1 P23141 2/20 0.44
CXCL8 P10145 1/20 0.41
AKR1B1 P15121 2/20 0.41
AKR1A1 P14550 1/20 0.41
AKR1C3 P42330 1/20 0.40
AKR1C2 P52895 1/20 0.40
KDM4E B2RXH2 2/20 0.39
HSD17B10 Q99714 2/20 0.39
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
DHFR P00374 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1021069 0.85 KEAP1 (0.53) TSHRKEAP1DCLRE1BAGBL2CES2
SCHEMBL16429122 0.84 KEAP1 (0.52) TSHRKEAP1DCLRE1BCES2CES1
SCHEMBL65008 0.82 KEAP1 (0.50) KEAP1DCLRE1BCES2CES1KDM4E
SCHEMBL365167 0.82 KEAP1 (0.50) TSHRKEAP1DCLRE1BAPEX1CES2
SCHEMBL3769033 0.81 TSHR (0.50) TSHRDCLRE1BAGBL2CXCL8AKR1B1
Hydrochloric Acid SCHEMBL29118324 0.81 KEAP1 (0.48) KEAP1DCLRE1BCES2CES1KDM4E
SCHEMBL22341265 0.81 KEAP1 (0.48) TSHRKEAP1DCLRE1BCES2CES1
SCHEMBL21815740 0.81 KEAP1 (0.48) TSHRKEAP1DCLRE1BAGBL2APEX1
SCHEMBL13806629 0.81 KEAP1 (0.48) TSHRKEAP1DCLRE1BAGBL2APEX1
SCHEMBL29471363 0.80 TSHR (0.53) TSHRAGBL2CES2CES1CXCL8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025042797-A1 TRIM7 INHIBITORS AND USES THEREOF SHATTUCK LABS, INC. (US) 2025-02-27 WO disclosed
EP-1478624-B1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2010-09-08 EP disclosed
EP-1478624-B1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2010-09-08 EP disclosed
US-7713994-B2 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof WYETH LLC (US) 2010-05-11 US disclosed
US-7709500-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-05-04 US disclosed
US-7709500-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-05-04 US disclosed
US-7709500-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-05-04 US disclosed
CN-100564358-C The method of a kind of preparation 4-(3, the 4-dichlorophenoxy) piperidines ASTRAZENECA AB (SE) 2009-12-02 CN disclosed
EP-1963273-A2 SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITORS Wyeth a Corporation of the State of Delaware (US) 2008-09-03 EP disclosed
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof WYETH (US) 2008-04-10 US disclosed
CN-100352807-C substituted piperidine compounds ASTRAZENECA AB (SE) 2007-12-05 CN disclosed
WO-2007075783-A2 SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITOR WYETH (US) 2007-07-05 WO disclosed
CN-1907968-A Method for making 4-(3,4-dichlorophenoxy)piperidine ASTRAZENECA AB (SE) 2007-02-07 CN disclosed
CN-1633414-A Compound (I) ASTRAZENECA AB (SE) 2005-06-29 CN disclosed
US-20050107428-A1 Chemical compounds ASTRAZENECA AB (SE) 2005-05-19 US disclosed
EP-1478624-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2004-11-24 EP disclosed
WO-2003068743-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107428-A1 Chemical compounds CCR10, CCR3, CXCR5 TSHR 1684/4885KEAP1 684/4885DCLRE1B 3309/4885
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof SULT1E1, RECQL, HAX1 TSHR 2138/4885KEAP1 82/4885DCLRE1B 1596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.